Clinical Trial Update: The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating a kynurenine aminotransferase inhibitor in people with schizophrenia, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-02-11